Autoimmune Diseases / 2017 / Article / Tab 2

Research Article

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

Table 2

The percent PLN patients with MPO-ANCA above specific thresholds compared to matching healthy and SLE without LN disease controls. The Department of Defense Serum Repository could not assign a matching disease control for one patient. The samples for a second control were lost in processing. Not all patients had samples available for each subgroup time period. If multiple serum samples were present for a patient in a specific subgroup analysis time period, the highest antibody level dictated group assignment. due to actual infinite value.
(a)

MPO-ANCACases
(%)
Healthy controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

(≥3 U/mL):
 All91 (21/23)26 (6/23)305.3–167<0.001
 <1 year88 (15/17)19 (3/16)334.7–226<0.001
 1–4 years87 (13/15)13 (2/15)425.2–347<0.001
 >4 years69 (11/16)25 (4/16)6.61.4–310.03
(≥6 U/mL)
 All57 (13/23)0 (0/23)<0.001
 <1 year59 (10/17)0 (0/16)<0.001
 1–4 years7 (1/15)0 (0/15)1.0
 >4 years19 (3/16)0 (0/16)0.23

(b)

MPO-ANCACases
(%)
Disease controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

(≥3 U/mL):
 All91 (21/23)43 (9/21)142.6–76<0.001
 <1 year88 (15/17)39 (5/13)121.9–760.007
 1–4 years87 (13/15)38 (6/16)111.8–660.009
 >4 years69 (11/16)44 (7/16)2.80.7–120.29
(≥6 U/mL)
 All57 (13/23)5 (1/21)263.0–228<0.001
 <1 year59 (10/17)8 (1/13)171.8–1640.006
 1–4 years7 (1/15)6 (1/16)1.10.1–191.0
 >4 years19 (3/16)0 (0/16)0.5–0.23

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.